Maryland Senate Bill SB562

Maryland 2026 Regular Session

• Introduced: 2/4/26
• Refer: 2/4/26
• Report Pass: 3/9/26
• Engrossed: 3/12/26
• Refer: 3/13/26
• Report Pass: 4/1/26
• Enrolled: 4/3/26
• Chaptered: 4/14/26
• Passed: 4/14/26

Caption

State Board of Pharmacy - Prescriber-Pharmacist Agreements - Treatment of Opioid Use Disorders

Impact

The proposed amendments under SB 562 will fundamentally change the regulatory landscape for treatment of opioid use disorders within Maryland. By enabling pharmacists to directly participate in the therapeutic management of opioid addiction, the bill may increase access to necessary treatments, potentially reducing barriers for patients seeking care. This legislative change aligns with broader public health initiatives aimed at addressing the opioid crisis by expanding treatment options and encouraging a more integrated healthcare approach.

Summary

Senate Bill 562 seeks to amend current regulations surrounding the treatment of opioid use disorders by facilitating prescriber-pharmacist agreements. It allows licensed certified midwives to enter into therapy management contracts, removing the previous requirement for authorized prescribers to submit these agreements to the regulating health occupations board. The bill specifically permits pharmacists to treat opioid use disorders through controlled dangerous substances therapy, contingent upon them requesting data from the Prescription Drug Monitoring Program before initiating or modifying therapy. This aims to streamline the treatment process and enhance collaboration among healthcare professionals.

Sentiment

General sentiment towards SB 562 appears supportive, particularly among healthcare professionals advocating for improved treatment mechanisms for individuals with opioid use disorders. However, there is an underlying concern regarding the oversight and regulatory framework ensuring the safe use of controlled substances by pharmacists. Advocates argue that increased pharmacist involvement could lead to better patient outcomes, while skeptics caution against the risks associated with loosening restrictions on who can manage opioid-related treatments.

Contention

Notable points of contention have emerged regarding the potential implications of allowing pharmacists to initiate and manage controlled substances therapy without stringent oversight from health boards. Critics express worries about the adequacy of training and the potential for misuse of medication protocols. Furthermore, the bill raises questions about where the lines are drawn regarding the scope of practice for pharmacists, who may face challenges in balancing their new roles with traditional pharmacy duties. There are calls for ensuring robust monitoring systems to prevent abuse and safeguard patient health.